RECORDING: Professionals’ Conference – 27 September 2024
A recording of the Retina UK Professionals' Conference on 27 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.
Search results
A recording of the Retina UK Professionals' Conference on 27 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.
Cataracts and macular oedema are both associated with inherited sight loss and may respond to treatment.
A research project funded by Retina UK helped pave the way to a new gene therapy that has recently produced encouraging results in two young people with achromatopsia, a condition that causes complete colour-blindness and poor overall vision from birth.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
It was previously believed that female carriers of X-linked inherited retinal diseases (IRDs) like X-linked retinitis pigmentosa (RP and Choroideremia) remained unaffected by sight loss.
Disulfiram (Antabuse), FDA-approved for deterring alcohol, is in a phase 1 trial at the University of Washington to improve vision in retinitis pigmentosa.
UK researchers have discovered that passing a weak electrical current between electrodes on a person’s scalp may lead to a reduction in frequency of the visual hallucinations experienced by some people living with sight loss.
A round-up of the latest research into inherited retinal conditions - February 2024.